+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Ischemic Stroke

  • ID: 5141804
  • Report
  • October 2020
  • Region: Global
  • 44 pages
  • Datamonitor Healthcare

Enquire about COVID-19 updates for this product.

Enquire Now
This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.

Key Takeaways

The publisher estimates that in 2018, there were approximately 82.3 million prevalent cases of ischemic stroke worldwide, and forecasts that number to increase to 88.0 million prevalent cases by 2027.

The approved drugs in the ischemic stroke space focus on a wide variety of targets. Most approved drugs are administered orally, with two drugs administered intravenously and one drug administered subcutaneously.

The majority of industry-sponsored drugs in active clinical development for ischemic stroke are in Phase II, with only one drug in the NDA/BLA phase.

Therapies in active clinical development for ischemic stroke focus on a wide variety of targets and include small molecules, peptides, and cell-based therapies.

High-impact upcoming events for drugs in the ischemic stroke space comprise topline Phase II trial results for Trans Sodium Crocetinate and TMS-007, topline Phase IIb trial results for ReN001, topline Phase III trial results for Cirara, and an expected PDUFA date as well as a supplemental CHMP opinion for Brilinta.

The overall likelihood of approval of a Phase I stroke asset is 1.3%, and the average probability a drug advances from Phase III is 16.7%. Drugs, on average, take 10.2 years from Phase I to approval, compared to 9.8 years in the overall neurology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for stroke have been in the early and midphases of development, with 70% of trials in Phase I-II, and 30% in Phase III-IV.

The US has a substantial lead in the number of stroke clinical trials globally. Germany leads the major European markets, while China has the top spot in Asia.

Clinical trial activity in the stroke space is dominated by completed trials. Roche has the highest number of completed clinical trials for stroke, with 21 trials.

Roche leads industry sponsors with the highest overall number of clinical trials for stroke, followed by Boehringer Ingelheim and Daiichi Sankyo.
Note: Product cover images may vary from those shown
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
  • Disease definition
  • Symptoms
  • Risk factors
  • Diagnosis
TREATMENT
  • Acute treatment of ischemic stroke
  • Long-term treatments
  • Palliative care
EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • SB623 for Ischemic Stroke (September 14, 2020)
  • DM199 for Ischemic Stroke (May 13, 2020)
  • NA-1 for Ischemic Stroke (February 20, 2020)
  • Fetzima for Ischemic Stroke (June 25, 2019)
  • Solitaire FR for Ischemic Stroke (April 30, 2019)
  • ReN001 for Ischemic Stroke (April 9, 2019)
KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
  • NDAs And More: Recent Submissions For FDA Approval
  • Medtronic Wins In England’s NICE Decision On Implantable Monitors For Stroke Patients; Biotronik And Abbott Lose
PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • Dainippon, SanBio Call Time On Stroke Cell Therapy Alliance
CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
BIBLIOGRAPHY
  • Prescription information
APPENDIX

List of Figures
  • Figure 1: Trends in prevalent cases of ischemic stroke, 2018-27
  • Figure 2: Overview of pipeline drugs for ischemic stroke in the US
  • Figure 3: Pipeline drugs for ischemic stroke, by company
  • Figure 4: Pipeline drugs for ischemic stroke, by drug type
  • Figure 5: Pipeline drugs for ischemic stroke, by classification
  • Figure 6: SB623 for Ischemic Stroke (September 14, 2020): Phase IIb - ACTIsSIMA
  • Figure 7: DM199 for Ischemic Stroke (May 13, 2020): Phase II - ReMEDy
  • Figure 8: NA-1 for Ischemic Stroke (February 20, 2020): Phase III - ESCAPE-NA1
  • Figure 9: Key upcoming events in ischemic stroke
  • Figure 10: Probability of success in the neurology pipeline
  • Figure 11: Clinical trials in stroke
  • Figure 12: Top 10 drugs for clinical trials in stroke
  • Figure 13: Top 10 companies for clinical trials in stroke
  • Figure 14: Trial locations in stroke
  • Figure 15: Stroke trials status
  • Figure 16: Stroke trials sponsors, by phase
List of Tables
  • Table 1: Prevalent cases of ischemic stroke, 2018-27
  • Table 2: Marketed drugs for ischemic stroke
  • Table 3: Pipeline drugs for ischemic stroke in the US
  • Table 4: SB623 for Ischemic Stroke (September 14, 2020)
  • Table 5: DM199 for Ischemic Stroke (May 13, 2020)
  • Table 6: NA-1 for Ischemic Stroke (February 20, 2020)
  • Table 7: Fetzima for Ischemic Stroke (June 25, 2019)
  • Table 8: Solitaire FR for Ischemic Stroke (April 30, 2019)
  • Table 9: ReN001 for Ischemic Stroke (April 9, 2019)
Note: Product cover images may vary from those shown
Adroll
adroll